Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques  Juliette Hordeaux, Christian Hinderer,

Slides:



Advertisements
Similar presentations
Monocyte Traffic, Dorsal Root Ganglion Histopathology, and Loss of Intraepidermal Nerve Fiber Density in SIV Peripheral Neuropathy  Jessica R. Lakritz,
Advertisements

Volume 20, Issue 2, Pages (February 2012)
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Athena Kalyvas, Samuel David  Neuron 
Volume 22, Issue 4, Pages (April 2014)
D.W Huang, L McKerracher, P.E Braun, S David  Neuron 
Molecular Therapy - Methods & Clinical Development
Volume 16, Issue 8, Pages (August 2008)
Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation  Stefan Bittner, Tobias Ruck, Kerstin Göbel, Christian Henschel,
P. James B. Dyck, MD, Jennifer A. Tracy, MD  Mayo Clinic Proceedings 
Volume 22, Issue 8, Pages (August 2014)
Regeneration of Sensory Axons within the Injured Spinal Cord Induced by Intraganglionic cAMP Elevation  Simona Neumann, Frank Bradke, Marc Tessier-Lavigne,
Volume 24, Issue 2, Pages (February 2016)
Volume 19, Issue 2, Pages (February 2011)
Volume 22, Issue 12, Pages (December 2014)
Molecular Therapy - Methods & Clinical Development
Intraspinal AAV Injections Immediately Rostral to a Thoracic Spinal Cord Injury Site Efficiently Transduces Neurons in Spinal Cord and Brain  Michelle.
Regeneration of Dorsal Column Fibers into and beyond the Lesion Site following Adult Spinal Cord Injury  Simona Neumann, Clifford J Woolf  Neuron  Volume.
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 25, Issue 6, Pages (June 2017)
Volume 5, Issue 5, Pages (November 1996)
Volume 6, Issue 3, Pages (September 2002)
Volume 20, Issue 5, Pages (May 2012)
Volume 22, Issue 3, Pages (March 2014)
Volume 24, Issue 5, Pages (May 2016)
Volume 23, Issue 12, Pages (December 2015)
Volume 20, Issue 2, Pages (February 2012)
Volume 19, Issue 11, Pages (November 2011)
Volume 20, Issue 10, Pages (October 2012)
Volume 16, Issue 8, Pages (August 2008)
A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae  Yang Wu, Liangyu Jiang,
Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca2+ adenosine triphosphatase delivered by molecular cardiac.
Volume 25, Issue 11, Pages (November 2017)
Volume 19, Issue 2, Pages (February 2011)
Volume 18, Issue 4, Pages (April 2010)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 11, Pages (November 2010)
Molecular Therapy - Methods & Clinical Development
Volume 13, Issue 3, Pages (March 2006)
Volume 25, Issue 12, Pages (December 2017)
Molecular Therapy - Methods & Clinical Development
Volume 19, Issue 2, Pages (February 2011)
Volume 24, Issue 7, Pages (July 2016)
Volume 25, Issue 6, Pages (June 2017)
Volume 23, Issue 3, Pages (March 2015)
Volume 18, Issue 1, Pages (January 2010)
Volume 6, Issue 1, Pages (July 2002)
Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice  Mohammad A.
Volume 18, Issue 1, Pages (January 2010)
Molecular Therapy - Methods & Clinical Development
Volume 18, Issue 9, Pages (September 2010)
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Volume 22, Issue 2, Pages (February 2014)
Volume 18, Issue 7, Pages (July 2010)
Hsp70 Gene Transfer by Adeno-associated Virus Inhibits MPTP-Induced Nigrostriatal Degeneration in the Mouse Model of Parkinson Disease  Zhizhong Dong,
Volume 19, Issue 2, Pages (February 2011)
Nicholas M. Kanaan, Rhyomi C. Sellnow, Sanford L
Volume 17, Issue 5, Pages (May 2009)
Kasey L Jackson, Robert D Dayton, Ronald L Klein 
Volume 21, Issue 11, Pages (November 2013)
Volume 22, Issue 3, Pages (March 2014)
Systemic PPARγ Ligation Inhibits Allergic Immune Response in the Skin
Volume 20, Issue 9, Pages (September 2012)
Volume 19, Issue 5, Pages (May 2011)
Ultrasound-Mediated Gene Therapy in Swine Livers Using Single-Element, Multi-lensed, High-Intensity Ultrasound Transducers  Misty L. Noble-Vranish, Shuxian.
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs  Anna Majowicz,
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques  Juliette Hordeaux, Christian Hinderer, Tamara Goode, Elizabeth L. Buza, Peter Bell, Roberto Calcedo, Laura K. Richman, James M. Wilson  Molecular Therapy - Methods & Clinical Development  Volume 10, Pages 68-78 (September 2018) DOI: 10.1016/j.omtm.2018.06.004 Copyright © 2018 Terms and Conditions

Figure 1 CSF WBC Counts in Rhesus Macaques Injected with Suboccipital AAV9.hIDS Left panel, animals without IS; right panel, animals with IS (rapamycin and MMF with withdrawal of MMF on day 60). A minimal-to-mild CSF mononuclear pleocytosis (mainly lymphocytic) was observed in three HD, one LD, and one LD IS animal. The dashed line indicates the threshold for abnormal CSF cell counts in rhesus macaques (5 cells/μL CSF). Values were excluded when a blood contamination above 500 erythrocytes/μL was observed. Molecular Therapy - Methods & Clinical Development 2018 10, 68-78DOI: (10.1016/j.omtm.2018.06.004) Copyright © 2018 Terms and Conditions

Figure 2 Immune Responses to the Transgene Product and Capsid in Rhesus Macaques Injected with Suboccipital AAV9.hIDS (A) Serum (left) and CSF (right) anti-hIDS immune response measured by ELISA. Results are shown as averages per group with standard deviations as error bars. Humoral responses were low overall and were transient in the CSF. (B) AAV9 NAb titers in serum (left) and CSF (right). (C) Interferon-gamma ELISPOT responses in PBMCs, lymphocytes from spleen, and bone marrow toward hIDS transgene (left) and AAV9 capsid (right) peptide pools. Molecular Therapy - Methods & Clinical Development 2018 10, 68-78DOI: (10.1016/j.omtm.2018.06.004) Copyright © 2018 Terms and Conditions

Figure 3 Representative CNS and Peripheral Nervous System Histopathologic Findings in Rhesus Macaques Injected with Suboccipital AAV9.hIDS (A–C) The majority of animals had minimal-to-mild neuronal cell-body degeneration in the DRG characterized by neurodegeneration (arrow, A), satellitosis, and mononuclear cell infiltrates that surrounded and invaded neuronal cell bodies (arrowhead, A). Mononuclear cell infiltrates were predominantly composed of CD3+ T cells (arrowheads, B) with fewer CD20+ B cells (arrowheads, C). (D) All animals from test-article-treated groups had an axonopathy of the dorsal white matter tracts of the spinal cord, which was bilateral and characterized by dilated myelin sheaths with and without myelomacrophages (arrows), consistent with axonal degeneration. (E) In a few animals, a similar axonopathy (arrows) was observed in the sciatic nerve. H&E, scale bars, 200 μm (A), 100 μm (D and E). CD3 or CD20 IHC, scale bars, 100 μm (B and C). (F) Individual DRG (left) and axonopathy (right) cumulative scores defined as the sum of cervical, thoracic, and lumbar segment scores with 1 as minimal, 2 as mild, 3 as moderate, 4 as marked, and 5 as severe; no animal had a score higher than 2 in any analyzed segment. Error bars represent standard deviation. Molecular Therapy - Methods & Clinical Development 2018 10, 68-78DOI: (10.1016/j.omtm.2018.06.004) Copyright © 2018 Terms and Conditions

Figure 4 Biodistribution in Tissues, Urine, and Stools in Rhesus Macaques Injected with Suboccipital AAV9.hIDS (A) Vector GCs in the central and peripheral nervous systems (left) and peripheral organs (right) 90 days after vector administration. Averages per group with SD as error bars. (B) Vector GC shedding in urine (GC/12 μL urine, limit of detection 25 GC) and stools (GC/μg DNA, limit of detection 50 GC) at baseline and days 5, 30, and 90. Molecular Therapy - Methods & Clinical Development 2018 10, 68-78DOI: (10.1016/j.omtm.2018.06.004) Copyright © 2018 Terms and Conditions